BioSpace News Archive

AB Science SA announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease in the renowned international peer-reviewed journal Alzheimer’s Research & Therapy.

Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company as at 28 February 2022 consists of 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury.

DENTSPLY SIRONA Inc. announced its financial results for the fourth quarter and full year 2022.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and the full year ended December 31, 2022.

SpringWorks Therapeutics, Inc. reported financial results for the fourth quarter and full-year periods ended December 31, 2022 and provided an update on recent company developments.

Clover Health Investments, Corp. today reported financial results for the fourth quarter and full year 2022.

Mallinckrodt plc (NYSE American: MNK) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported results for the fourth quarter ended December 30, 2022.

RedHill Biopharma Ltd. announced that the Radiation and Nuclear Countermeasures Program, of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has selected opaganib1 for the nuclear medical countermeasures product development pipeline as a potential treatment for Acute Radiation Syndrome.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced its continued investment in endodontics, with a specific focus on clinical training and education.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced top-line results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug, in dry eye disease patients.